CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · Real-Time Price · USD
6.60
+0.09 (1.38%)
At close: Dec 5, 2025, 4:00 PM EST
6.55
-0.05 (-0.76%)
After-hours: Dec 5, 2025, 7:09 PM EST
CNS Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for CNS Pharmaceuticals stock has a target of 20, which predicts an increase of 203.03% from the current stock price of 6.60.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 12, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for CNS Pharmaceuticals is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $20 | Hold → Strong Buy | Upgrades | $20 | +203.03% | Sep 12, 2025 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 25, 2025 |
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $300 | Hold → Strong Buy | Upgrades | $300 | +4,445.45% | Sep 10, 2024 |
| Brookline Capital | Brookline Capital | Strong Buy Initiates $9,000,000 | Strong Buy | Initiates | $9,000,000 | +136,363,536.36% | Feb 2, 2021 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $9,900,000 | Strong Buy | Initiates | $9,900,000 | +149,999,900.00% | Aug 24, 2020 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-34.38
from -466.45
EPS Next Year
-10.38
from -34.38
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -32.98 | -6.89 | ||
| Avg | -34.38 | -10.38 | ||
| Low | -35.28 | -13.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.